Clinical Practice of Azvudine for the Treatment of COVID-19
OBJECTIVE To investigate the clinical efficacy and its effective time of azvudine in the treatment of patients with mild to moderate COVID-19,and to observe its side effects.METHODS The clinical data of hospitalized patients,who were diagnosed with mild to moderate COVID-19 and voluntarily treated with azvudine in the Sixth Affiliated Hospital of South China University of Technology from December 15,2022 to January 15,2023,were retrospectively collected.The symptoms of cough,expectoration,chest tightness,shortness of breath,lung imaging and oxygenation were analyzed,the common types of adverse reactions and their incidence were observed.RESULTS There were 36 cases included in this study,the clinical symptoms of 11 patients with moderate COVID-19 were all improved,and the improvement rate of 25 patients with mild COVID-19 was 64％,including 19 cases with cough and expectoration at admission,14 cases improved(52.6％)or even recovered(21.1％)after taking azvudine,the total effective rate was 73.7％,the average time needed for medication was 5.5-5.8 days,including 16 patients with active dyspnea at admission,14 patients with dyspnea improved(50.0％)or even disappeared(37.5％)after taking azvudine,the total effective rate was 87.5％,the average time of drug administration was 3.4-4.3 days.Azvudine was effective in 2 patients with chest tightness at admission.There were showed that their pulmonary oxygenation were improved(100％),their pulmonary lymphocyte were in remission(62.5％)andpulmonary imaging findings showed recovery(72.2％).Among them,4 cases(11.1％)had grade 3-4 transaminase elevation,which could be recovered spontaneously after drug withdrawal.CONCLUSION Azvudine can accelerate the improvement of respiratory symptoms after COVID-19 infection.However,it is necessary to pay attention to its hepatotoxic adverse reactions during clinical use.
万方数据
维普
